2026 Retrospective Note: The epidemiological projections established in this 2017 paper remain an important framework to tracking historical policy impacts. Notably, the March 2026 reclassification of preoperative autologous blood donation (PAD) to a matter of personal conscience represents the first systemic institutional shift targeting the very baseline numbers analyzed above, adding a critical new chapter to prospective mortality tracking and patient autonomy.

The Impact of the Watchtower Blood Prohibition

While the Watchtower has never published either actual statistics or estimates concerning the impact of the Jehovah’s Witness blood policy, it is well recognized within the medical literature that refusal of blood transfusion has, in some circumstances, been associated with preventable mortality among patients who decline transfusion because of religious conviction.1 2 3

It would have been possible for the Watch Tower Society to collect aggregate information concerning deaths associated with its blood policy, as the organization maintains detailed records regarding its membership and congregation activity. In addition, Hospital Liaison Committee (HLC) and Hospital Visit Committee (HVC) representatives are frequently involved in cases involving Jehovah’s Witness patients facing complex transfusion decisions. To date, however, the Watch Tower Society has not published aggregate mortality data related to the blood policy. The reasons for this are not publicly known. Some commentators have suggested that legal, institutional, or other considerations may have influenced this decision, although no official explanation has been provided.

Because no official mortality data are available, researchers have attempted to estimate the potential impact of the policy using published clinical studies and epidemiological extrapolation. AJWRB Medical Adviser Dr. Osamu Muramoto, M.D., and AJWRB Science Adviser Marvin Shilmer independently analyzed the available medical literature to estimate both the cumulative number of deaths that may have occurred since the introduction of the blood transfusion prohibition in 1945 and the number of deaths that may continue to occur annually under the current policy. Although these estimates necessarily rely on assumptions and should not be interpreted as observed mortality, they provide a useful framework for understanding the possible public health implications of the policy. The following sections review these published extrapolations and then update the estimates using current demographic data.

Dr. Muramoto’s Epidemiological Extrapolation

Dr. Osamu Muramoto, MD – AJWRB Medical Adviser

In 2001, Dr. Osamu Muramoto developed one of the earliest attempts to estimate the potential mortality associated with the Jehovah’s Witness blood policy using published clinical data. His analysis drew upon a study by Kitchens, Are transfusions overrated? Surgical outcome of Jehovah’s Witnesses, published in the February 1993 issue of The American Journal of Medicine.4 The study examined 1,404 “bloodless” surgical procedures performed on Jehovah’s Witness patients and reported that 1.4% of patients died with refusal of blood identified as either the primary or a contributing factor in their deaths.

Rather than applying the reported 1.4% mortality difference directly, Dr. Muramoto adopted a deliberately conservative approach. To allow for uncertainty—including the possibility that some patients might have died irrespective of transfusion status—he rounded the figure down to 1.0%. Expressed differently, his extrapolation assumed that approximately one additional death would occur for every one hundred Jehovah’s Witness patients undergoing major medical treatment in which blood transfusion would ordinarily be considered.4

At that time, the American Association of Blood Banks reported that approximately 4 million patients in the United States received blood transfusions each year from approximately 12.6 million donated units of blood. This represented roughly 15 patients per 1,000 population annually who required transfusion as part of their medical care.

The United States Jehovah’s Witness population at that time was approximately one million members. Applying the same utilization rate suggested that roughly 15,000 Jehovah’s Witnesses each year would experience medical conditions in which transfusion would ordinarily be indicated. Applying the conservative 1% excess mortality assumption yielded an estimated 150 additional deaths annually in the United States attributable to refusal of blood transfusion.

Because Jehovah’s Witnesses constitute a global religious organization, Dr. Muramoto’s approach can be extended beyond the United States by applying the same conservative methodology to worldwide publisher statistics. For additional conservatism, AJWRB excludes the years 1945–1960, although the blood transfusion prohibition was introduced in 1945. During that earlier period, adherence to the policy was not enforced through the formal disciplinary measures introduced in 1961. Excluding those years likely results in an underestimate of cumulative mortality but avoids making assumptions regarding levels of compliance during the policy’s formative years.

Using the Watch Tower Society’s published annual publisher reports, AJWRB calculated an average worldwide publisher population of 3,957,868 between 1961 and 2016. Applying Dr. Muramoto’s conservative extrapolation to this population produces an estimated 33,246 cumulative deaths over the 56-year period, representing an average of approximately 594 deaths per year, increasing to an estimated 1,220 deaths in 2016 as the global Jehovah’s Witness population expanded.

These figures should be understood as epidemiological extrapolations rather than observed mortality. They rely on published clinical data and several simplifying assumptions, including the application of United States transfusion utilization rates to an international population. At the same time, the estimates may also understate mortality in some settings, particularly in earlier decades and in lower-resource healthcare systems where access to modern blood conservation techniques has historically been limited. Because no official mortality data have been published, the true number of deaths associated with the policy cannot presently be determined. Nevertheless, Dr. Muramoto’s methodology provides a transparent and conservative framework for estimating the possible public health impact of the blood transfusion prohibition.

A Second Epidemiological Extrapolation

In 2012, Marvin Shilmer, a former Jehovah’s Witness official and AJWRB Science Adviser, independently prepared a second estimate of the potential mortality associated with the Watchtower’s blood policy.

His analysis drew upon a more recent multicenter observational study by Beliaev et al., Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anemia, published in Vox Sanguinis in 2012.5

The study compared Jehovah’s Witness patients who refused red blood cell transfusions with matched patients who accepted transfusion. Data were collected from four public hospitals in New Zealand between 1998 and 2007. Patients younger than sixteen years of age and those with advanced cancer were excluded. Among 103 Jehovah’s Witness patients with severe symptomatic anemia, 21 patients (20.4%) died, whereas mortality in the matched transfused group was 1.9%. The observed difference in mortality between the two groups was 18.5 percentage points, suggesting substantially higher mortality among patients who refused transfusion under the conditions studied.

Expressed differently, had the Jehovah’s Witness cohort experienced the same mortality rate as the matched transfused patients, approximately two deaths would have been expected instead of twenty-one during the ten-year study period. This represents approximately nineteen excess deaths, or an average of 1.9 excess deaths per year. During the same period, New Zealand averaged approximately 12,700 Jehovah’s Witness publishers, yielding an estimated annual excess mortality factor of approximately 0.015% of the publisher population. Notably, this independently derived estimate closely parallels the conservative annual mortality factor calculated by Dr. Muramoto using an entirely different dataset.

Because both Dr. Muramoto’s and Marvin Shilmer’s analyses converged on an annual excess mortality factor of approximately 0.015%, this figure provides a useful basis for estimating the possible population-level impact of the blood policy.

Using the Watch Tower Society’s published annual report, which listed 8,132,358 publishers during the 2016 service year, application of the 0.015% annual excess mortality factor yields an estimated 1,220 excess deaths worldwide during that year among Jehovah’s Witnesses who refused blood transfusion. This figure represents an epidemiological extrapolation rather than observed mortality, but it illustrates the potential magnitude of the policy’s public health impact.

Because the blood transfusion prohibition has existed since 1945, and because formal disciplinary enforcement began in 1961, AJWRB used worldwide publisher statistics beginning with 1961 to estimate cumulative mortality. Applying the same conservative annual mortality factor to the average worldwide publisher population between 1961 and 2016 produces an estimated 33,246 cumulative excess deaths over that fifty-six-year period. As with all epidemiological extrapolations, this figure should be interpreted as an estimate rather than a documented count of observed deaths.

Conservative Estimates of Blood Policy Mortality

Even these estimates are intentionally conservative. As discussed above, Dr. Muramoto reduced the 1.4% excess mortality observed in the Kitchens study to 1.0% before performing his extrapolation in order to avoid overstating the potential impact of the policy.

If the original 1.4% excess mortality reported by Kitchens were applied without this conservative adjustment, the resulting extrapolation would increase by approximately 40%, yielding an estimated 1,708 excess deaths worldwide in 2016 and approximately 46,544 cumulative excess deaths between 1961 and 2016.

Because these calculations depend upon different assumptions, they should be regarded as a range of epidemiological extrapolations rather than precise mortality counts. The true number of deaths associated with the blood policy cannot presently be determined because no official mortality data have been published. Nevertheless, the convergence of two independent analyses suggests that the cumulative public health impact of the policy may be substantial.

These estimates may surprise many readers, particularly Jehovah’s Witnesses, because relatively few individual cases receive public attention. By contrast, physicians working in trauma care, hematology, obstetrics, surgery, and critical care are familiar with the serious risks associated with profound anemia when transfusion is declined. AJWRB has documented numerous individual cases reported by patients, family members, and healthcare professionals, but these represent only a small proportion of cases that occur worldwide.

Several factors contribute to the limited public visibility of these deaths. Most occur in ordinary hospital settings rather than under circumstances that attract media attention. Privacy legislation in many countries, including the United States, appropriately protects patient confidentiality, and hospitals rarely publicize individual outcomes. Consequently, cases generally become publicly known only when:

  • AJWRB members or former members voluntarily report their experiences.
  • Non-Jehovah’s Witness family members choose to speak publicly or contact the media.
  • Physicians or hospitals seek judicial authorization to administer blood transfusions to minors.

This distinction between individual visibility and population-level risk has important implications for informed consent. Patients frequently evaluate risk based upon personal experience and anecdotal observation rather than epidemiological data. When adverse outcomes are widely dispersed across a large international population, the underlying risk may remain largely invisible to individual members despite producing measurable mortality at the population level.

In addition to limited visibility, many Jehovah’s Witnesses have been taught that blood transfusion should be avoided not only for religious reasons but also because it presents unacceptable medical risks. For decades, Watchtower publications have emphasized the potential complications of transfusion while giving comparatively less attention to the substantial evidence supporting its life-saving role in appropriate clinical circumstances.6 This historical messaging may influence how some patients perceive the balance of risks and benefits when considering transfusion.

The following quotation from the Watchtower’s website, reproduced as it appeared on May 9, 2017, illustrates this broader emphasis:

Although many elective surgical procedures can be performed successfully using modern blood conservation techniques, the clinical situations most strongly associated with transfusion-related survival benefit are frequently those involving major trauma, severe obstetric hemorrhage, gastrointestinal bleeding, and profound symptomatic anemia. In these settings, effective alternatives to red blood cell transfusion may be limited or unavailable.

Severe anemia remains one of the principal mechanisms by which refusal of transfusion can become life-threatening. When oxygen delivery falls below the metabolic requirements of vital organs, progressive tissue injury and organ failure may occur despite otherwise appropriate medical management. Patient Blood Management and blood conservation strategies have substantially improved outcomes and should be employed whenever appropriate. Nevertheless, these approaches are complementary to—not replacements for—blood transfusion in circumstances where severe anemia or hemorrhage cannot otherwise be corrected. In such cases, the availability of transfusion remains an important component of modern medical care.

Institutional Coercion and Informed Consent

The Watchtower Society teaches that its blood policy is derived from biblical commands regarding the sanctity of blood. Critics, however, have argued that the organization’s interpretation extends beyond the biblical text and relies upon specific theological inferences that remain contested among biblical scholars and former members.

Additionally, failure to comply may result in organizationally mandated shunning by other JW members, and lifelong friends who will be prohibited from eating a meal or even speaking to the non-compliant JW who does not follow the policy, or even voices disagreement, for that matter. The choice a severely anemic Jehovah’s Witness faces is grave.  For some individuals, the prospect of mandated shunning and the potential loss of family, friends, and community may function as a significant source of social pressure when medical decisions involving blood transfusion are considered. From the perspective of clinical bioethics, such pressures may complicate assessments of voluntariness, one of the central components of informed consent. For clinicians unfamiliar with these organizational dynamics, it may not always be apparent that a patient’s stated refusal reflects not only sincerely held religious beliefs but also longstanding institutional, familial, and social influences. Appreciating this broader context allows physicians to better evaluate voluntariness while respecting patient autonomy and maintaining appropriate confidentiality.

1. Are transfusions overrated? Surgical outcome of Jehovah’s Witnesses. Kitchens CS. The American Journal of Medicine. 1993 Feb; p.117-119. http://www.amjmed.com/article/0002-9343(93)90171-K/pdf

2. Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anemia. Beliaev et al. VoxSanguinis 2012 July 103(1):18-24. https://www.ncbi.nlm.nih.gov/pubmed/22150804

3. Refusal of blood transfusion by Jehovah’s Witness women: a survey of current management in obstetric and gynaecological practice in the UK. Sahana Gupta et al. Blood Transfusion 2012 Oct; 10(4): 462-470. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496240/

4. https://www.bmj.com/rapid-response/2011/10/28/risk-blood-transfusion-illegal-breach-confidentiality-addendum-reply-furul

5. https://ajwrb.org/marvin-shilmers-2012-estimate-of-jw-blood-deaths

6. https://www.ajwrb.org/clinical-resources-bioethical-guidelines-for-healthcare-providers/institutional-messaging-and-the-complication-of-informed-consent

The risks associated with blood transfusion are well recognized within modern medicine and are routinely discussed as part of the informed consent process. Over the past several decades, advances in donor screening, infectious disease testing, and transfusion practices have substantially improved the safety of the blood supply. However, some institutional publications have continued to emphasize historical or uncommon transfusion risks in ways that may not fully reflect contemporary clinical evidence.

Conversely, while avoiding transfusion may occasionally prevent transfusion-related complications, the available evidence indicates that these benefits are relatively uncommon compared with the well-documented survival benefit of transfusion for appropriately selected patients experiencing severe hemorrhage or symptomatic anemia. Consequently, incorporating transfusion-related complications into the epidemiological models presented in this article would not be expected to materially alter the overall mortality estimates. http://www.bmj.com/rapid-response/2011/10/28/risk-blood-transfusion-illegal-breach-confidentiality-addendum-reply-furul

A Note on Qualitative Patient Narratives:

The epidemiological data and statistical extrapolations presented in the text above are intended for clinical and bioethical review. However, AJWRB recognizes that behind every demographic statistic is a profound personal impact. The comment forum below is maintained as an open space for current members, former members, and their families to share their lived experiences regarding the blood prohibition. Please note that while these community-generated narratives are anecdotal and remain strictly distinct from our clinical data, we preserve them as vital qualitative perspectives on the real-world consequences of institutional medical directives.